Oncocyte Corp

For the period ended Jun 30, 2024. Filed Aug 8, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 8, 2024

IMDX$2.47-1.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

Three Months Ended · Six Months Ended
June 30, · June 30,
2024 · 2023 · 2024 · 2023
Net revenue		$104		$463		$280	$760
Cost of revenues		32		169		141	434
Cost of revenues – amortization of acquired intangibles		22		22		44	44
Gross profit		50		272		95	282
Operating expenses:
Research and development		2,453		2,435		4,765	4,562
Sales and marketing		853		805		1,699	1,500
General and administrative		2,407		3,531		5,080	6,943
Change in fair value of contingent consideration		(1,031)		1,795		2,281	(16,512)
Impairment loss		-		-		-	4,950
Impairment loss on held for sale assets		-		-		169	1,283
Total operating expenses		4,682		8,566		13,994	2,726
Loss from operations		(4,632)		(8,294)		(13,899)	(2,444)
Other (expenses) income:
Interest expense		(8)		(14)		(23)	(25)
Unrealized (loss) gain on marketable equity securities		-		(24)		-	97
Other income (expenses), net		110		(1)		263	(2)
Total other income (expenses)		102		(39)		240	70
Loss from continuing operations		(4,530)		(8,333)		(13,659)	(2,374)
Loss from discontinued operations (Note 11)		-		-		-	(2,926)
Net loss		$(4,530)		$(8,333)		$(13,659)	$(5,300)
Net loss per share (Note 2):
Net loss from continuing operations - basic and diluted		$(4,587)		$(8,644)		$(13,922)	$(2,915)
Net loss from discontinued operations - basic and diluted	$	-	$	-	$	-	$(2,926)
Net loss attributable to common stockholders - basic and diluted		$(4,587)		$(8,644)		$(13,922)	$(5,841)
Net loss from continuing operations per share - basic and diluted		$(0.36)		$(1.07)		$(1.32)	$(0.41)
Net loss from discontinued operations per share - basic and diluted	$	-	$	-	$	-	$(0.42)
Net loss attributable to common stockholders per share - basic and diluted		$(0.36)		$(1.07)		$(1.32)	$(0.83)
Weighted average shares outstanding - basic and diluted		12,870		8,090		10,567	7,030

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.